Ranibizumab in Myopic Choroidal Neovascularization: A Subgroup Analysis by Ethnicity, Age, and Ocular Characteristics in RADIANCE

Publisher： Karger

E-ISSN： 1423-0267|236|1|19-28

ISSN： 0030-3755

Source： Ophthalmologica, Vol.236, Iss.1, 2016-06, pp. : 19-28

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-Term Follow-Up of Myopic Choroidal Neovascularization Treated with Ranibizumab

By  

Ophthalmologica, Vol. 227, Iss. 1, 2011-11 ,pp. : 39-44

Karger

Access to resources Recommend Favorite

Intravitreal Ranibizumab for Predominantly Hemorrhagic Choroidal Neovascularization in Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 233, Iss. 2, 2015-01 ,pp. : 74-81

Karger

Access to resources Recommend Favorite

Progression of Myopic Maculopathy after Treatment of Choroidal Neovascularization

By  

Ophthalmologica, Vol. 231, Iss. 4, 2014-03 ,pp. : 211-220

Karger

Access to resources Recommend Favorite

Ranibizumab Treatment for Choroidal Neovascularization from Causes Other than Age-Related Macular Degeneration and Pathological Myopia

By  

Ophthalmologica, Vol. 225, Iss. 2, 2010-09 ,pp. : 81-88

Karger

Access to resources Recommend Favorite

Intravitreal Ranibizumab versus Thermal Laser Photocoagulation in the Treatment of Extrafoveal Classic Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 228, Iss. 2, 2012-05 ,pp. : 93-101

Karger

Access to resources Recommend Favorite